Market Place
Sourcing Support
All News #Library
Biotech
Larimar Therapeutics Reports Q4 & Full Year 2025 Financial Result
19 Mar 2026 //
GLOBENEWSWIRE
Larimar Therapeutics To Join March Investor Conferences
04 Mar 2026 //
GLOBENEWSWIRE
Larimar Therapeutics Plans $75M Public Offering
25 Feb 2026 //
GLOBENEWSWIRE
Larimar Therapeutics To Present At JP Morgan Healthcare Conf
18 Dec 2025 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
05 Nov 2025 //
GLOBENEWSWIRE
Larimar Therapeutics Hosts Conference On Nomlabofusp Program
28 Sep 2025 //
GLOBENEWSWIRE
Larimar Therapeutics Closes Public Offering & Option Exercise
31 Jul 2025 //
GLOBENEWSWIRE
Larimar Therapeutics Proposes Underwritten Public Offering
29 Jul 2025 //
GLOBENEWSWIRE
Larimar Therapeutics Reports First Quarter 2025 Financial Results
30 Apr 2025 //
GLOBENEWSWIRE
Larimar Updates Nomlabofusp Development and Q4 Result
24 Mar 2025 //
GLOBENEWSWIRE
Larimar To Present At Leerink Partners Healthcare Conference
03 Mar 2025 //
GLOBENEWSWIRE
Larimar Presents Data from Ph 1 & Ph 2 Nomlabofusp at ICAR 2024
18 Nov 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Q3 2024 Finacial Results
30 Oct 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Poster Presentations At ICAR
19 Sep 2024 //
GLOBENEWSWIRE
Larimar Therapeutics to Participate in Upcoming Investor Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
07 Aug 2024 //
GLOBENEWSWIRE
Larimar: FDA Removes Partial Hold On Nomlabofusp Friedreich`s Program
20 May 2024 //
GLOBENEWSWIRE
Larimar Announces the Dosing of the First Patient in Study for Nomlabofusp
11 Mar 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.